ClinicalTrials.gg
Not yet recruitingNCT07439510Updated Oct 9, 2026

A Study to Investigate the Effects and Safety of Codabakalner for the Treatment of FXS in Male Participants and Adult Participants With ADS

A Phase 2/3 interventional study of Codabakalner and Placebo in Fragile X Syndrome (FXS) and Autism Spectrum Disorder (ASD), sponsored by Spinogenix. Not yet recruiting. Open to male participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Spinogenix · Phase 2/3, Interventional, and Treatment

How we know

Updated Oct 9, 2026Start date movedEnrollment updated+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This is a Study to Investigate the Effects and Safety of Codabakalner for the Treatment of Fragile X Syndrome in Male Participants and Adult Participants with Autism Spectrum Disorders

Read the detailed description

This Phase 2b/3, randomized, double-blind, placebo-controlled, 2-part study will evaluate the efficacy, safety and tolerability of different dose regimens of codabakalner in adult male participants with Fragile X syndrome. The results from Phase 2b will be hypothesis generating and will inform the Phase 3 design.

Phase 2b, dose-regimen finding, 4-arm parallel design: Eligible participants will be randomized 1:1:1:1 to receive codabakalner at different doses or matched placebo. Participants will receive study intervention over 4 weeks and will be followed up for 4 weeks after last dose of study intervention.

Phase 3, 2-arm parallel design: Eligible participants will be randomized 1:1 to receive codabakalner or matched placebo. The dose of codabakalner administered in the Phase 3 will be defined based on analysis of Phase 2b. Participants will receive study intervention over 12 weeks and will be followed up for 4 weeks after last dose of study intervention.

02

Conditions studied

  • Fragile X Syndrome (FXS)
  • Autism Spectrum Disorder (ASD)

Keywords

  • Fragile X Syndrome
  • Fragile X Chromosome
  • cognitive outcomes
  • Autism
  • Autism Spectrum Disorder
03

In context

Fragile X Syndrome

115 studies on the registry are indexed under Fragile X Syndrome; 25 are open to participants now.

This study's planned enrollment of 120 is above the median of 54 across 92 interventional studies indexed under Fragile X Syndrome.

Browse Fragile X Syndrome studies →

Lead sponsor

Spinogenix is the lead sponsor of 9 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 9, 2026. See what changed

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Phase 2b: Adult males aged 18 to 45 years, inclusive Phase 3: Males aged 13-45 years, inclusive Mental age >/= 36mon
  • Diagnosis of Fragile X as confirmed with genetic testing and Stanford Binet testing or
  • Confirmed diagnosis ASD per DSM5-TR and EEG criteria
  • Patient must have caregiver
  • Must be in good health with no significant medical history

Exclusion criteria

Exclusion Criteria:

  • Any physical or psychological condition that prohibits study completion
  • Uncontrolled seizures or history of epilepsy with a seizure in the past 6 months.
  • Auditory or visual impairments that cannot be corrected
  • History of suicidal behaviour or suicidal ideation
  • Screening vital signs that are abnormal per protocol specification
  • that are abnormal and
  • History of substance abuse or dependence within 6 months
  • Other products within 30 days
  • Unable to swallow capsules
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Phase 2b: Active

    Phase 2b: Participants with FXS or ASD will be randomized to receive a daily dose of codabakalner daily for 4 weeks

    Drug: Codabakalner

  • Placebo comparator
    Phase 2b: Placebo

    Participants with FXS or ASD will be randomized to receive a daily dose of placebo over 4 weeks.

    Drug: Placebo

  • Active comparator
    Phase 3: Active

    Participants with FXS will be randomized to receive a daily dose of codabakalner determined from Phase 2b over 12 weeks

    Drug: Codabakalner

  • Placebo comparator
    Phase 3: Placebo

    Participants with FXS will be randomized to receive a daily dose of placebo for 12 weeks

    Drug: Placebo

Interventions

  • DrugCodabakalner

    synthetic small molecule

    Also known as: SPG601

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Phase 2b: FXS- Change from baseline in Total Cognition Composite Change Sensitive Score from the NIH-TCB

    The NIH Toolbox (NIH-TCB) Total Cognition Composite Change-Sensitive Score (CSS) is used to measure cognitive change over time. Higher scores indicate higher level of functioning. The scores typically span across the developmental range, often extending well above and below the 500-point mark depending on the age and cognitive ability of the individual.

    Time frame: 28 days

  2. Phase 2b: ASD - Change from Baseline at Day 28 on the Vineland Adaptive Behavior Scales in ASD(Vineland-III) Adaptive Behavior Composite Score

    Vineland Adaptive Behavior Composite (ABC) have a mean of 100 and a standard deviation of 15, where scores from 85 to 115 reflect expected or average adaptive functioning

    Time frame: 28 days

  3. Phase 3: FXS - Change from baseline in Total Cognition Composite score from the NIH-TCB

    The NIH Toolbox (NIH-TCB) Total Cognition Composite Change-Sensitive Score (CSS) is used to measure cognitive change over time. It is calculated by combining the Crystallized Composite (reading/vocabulary) and Fluid Composite (memory/executive function/speed) scores. Higher scores indicate higher level of functioning.

    Time frame: 12 weeks

Secondary outcomes

  1. Phase 2b: FXS- Change from baseline in Fluid Reasoning Composite Change Sensitive Scores from the NIH-TCB

    The Fluid Cognition Composite (FCC) from the NIH Toolbox Cognition Battery (NIHTB-CB) is designed to measure changes to neurological functioning. It combines scores from five tests (Dimensional Change Card Sort, Flanker, List Sorting, Pattern Comparison, and Picture Sequence Memory) to provide a measure of executive function, memory, and processing speed. Higher scores indicate higher level of functioning. Superior ability is 130, average is approx. 100 and less than 70 is impairment.

    Time frame: 28 days

  2. Phase 2b: FXS- Change from baseline in Flanker Scores from the NIH-TCB

    The Flanker test measures executive attention, inhibitory control, and attention by having participants identify the direction of a central arrow (or fish for young children) while ignoring surrounding flanking stimuli. Yields a standardized score scaled with a mean of 100 and a standard deviation of 15 (up to a maximum score of 130)

    Time frame: 28 days

  3. Phase 2b- FXS Change from Baseline at Day 28 on the Vineland Adaptive Behavior Scales (Vineland-III) Adaptive Behavior Composite Score

    Vineland Adaptive Behavior Composite (ABC) have a mean of 100 and a standard deviation of 15, where scores from 85 to 115 reflect expected or average adaptive functioning

    Time frame: 28 days

  4. Phase 2b: FXS and ASD: Change from baseline at Day 28 in Clinical global impression of severity (CGI-S) as assessed by the investigator

    This is a 7-point clinician-rated tool used to measure how ill a patient is at the time of assessment

    Time frame: 28 days

  5. Phase 2b: FXS and ASD: Change from baseline at Day 28 in Clinical global impression of improvement as assessed by the investigator

    The Clinical Global Impression-Improvement (CGI-I) scale is a clinician rated scale used to assess treatment response. The score ranges from 1 to 7 (with 1 being "very much improved", 4 being "no change" to 7 being "very much worse")

    Time frame: 28 days

  6. Phase 2b: FXS and ASD: Change from baseline at Day 28 in Caregiver global impression of change (CGI-C) as assessed by the caregiver

    The Caregiver Global Impression of Improvement (CGI-C) is a global measure to provide a caregiver's perspective of a subject's overall condition. The caregiver will use a 7-point scale to assess how the condition has changed from baseline. A higher number indicates worsening condition.

    Time frame: 28 days

  7. Phase 2b: FXS and ASD: Change from baseline at Day 28 in the Numerical Rating Scale as completed by the caregiver

    Numerical rating scale (NRS) scores based on patient-specific behaviors within the domains of Daily Function, Language, and Academic Skill. Caregiver will rate individual from 0 to 10, where 0 indicates 'worst problem' and 10 indicates' no problem at all.'

    Time frame: 28 days

  8. Phase 2b: FXS and ASD - Incidence, nature, and severity of adverse events (AEs) and serious adverse events (SAEs)

    Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Time frame: 28 days

  9. Phase 2b: FXS and ASD - Change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) throughout the study

    Prospective suicidality assessment is performed using the Columbia-Suicide Severity Rating Scale (C-SSRS), a questionnaire to evaluate suicidal ideation and behavior. Answer "yes" on item 4 or 5 of the Suicidal Ideation section or "yes" on any item of the Suicidal Behavior section is considered positive. Range is 2-25

    Time frame: 28 days

  10. Phase 2b: FXS and ASD - The PK parameters of codabakalner concentrations in plasma-Cmax

    Maximum concentration of drug in plasma following dose

    Time frame: 28 days

  11. Phase 2b: FXS and ASD: Change from baseline to Day 28 in EEG resting state relative power in the alpha, theta, and gamma bands during rest

    EEG power bands categorize brain electrical activity into five primary frequency ranges that reflect different states of arousal, sleep, and cognition

    Time frame: 28 days

  12. Phase 3: Change from baseline to week 12 in Total Cognition Composite score from the NIH-TCB

    The NIH Toolbox (NIH-TCB) Total Cognition Composite Change-Sensitive Score (CSS) is used to measure cognitive change over time. It is calculated by combining the Crystallized Composite (reading/vocabulary) and Fluid Composite (memory/executive function/speed) scores. Higher scores indicate higher level of functioning. The scores typically span across the developmental range, often extending well above and below the 500-point mark depending on the age and cognitive ability of the individual.

    Time frame: 12 weeks

  13. Phase 3: Incidence, nature, and severity of adverse events (AEs) and serious adverse events (SAEs)

    Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Time frame: 12 weeks

  14. Phase 3: Change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) throughout the study

    Prospective suicidality assessment is performed using the Columbia-Suicide Severity Rating Scale (C-SSRS), a questionnaire to evaluate suicidal ideation and behavior. Answer "yes" on item 4 or 5 of the Suicidal Ideation section or "yes" on any item of the Suicidal Behavior section is considered positive. Range is 2-25

    Time frame: 12 weeks

  15. Phase 3: Change from baseline to Week 4, Week 8, and Week 12 in Flanker from the NIH-TCB

    Flanker Inhibitory control will assess inhibitory control and attention through asking participant to focus on one stimuli will not focusing on any stimuli surrounding it.

    Time frame: 12 weeks

  16. Phase 3: Change from baseline to Week 4, Week 8, and Week 12 in Fluid Reasoning Composite Change Sensitive Scores from the NIH-TCB

    The Fluid Cognition Composite (FCC) from the NIH Toolbox Cognition Battery (NIHTB-CB) is designed to measure changes to neurological functioning. It combines scores from five tests (Dimensional Change Card Sort, Flanker, List Sorting, Pattern Comparison, and Picture Sequence Memory) to provide a measure of executive function, memory, and processing speed. Higher scores indicate higher level of functioning. Superior ability is 130, average is approx. 100 and less than 70 is impairment.

    Time frame: 12 weeks

  17. Phase 3: Change from baseline to week 4 and week 8 in Total Cognition Composite score from the NIH-TCB

    The NIH Toolbox (NIH-TCB) Total Cognition Composite Change-Sensitive Score (CSS) is used to measure cognitive change over time. It is calculated by combining the Crystallized Composite (reading/vocabulary) and Fluid Composite (memory/executive function/speed) scores. Higher scores indicate higher level of functioning. The scores typically span across the developmental range, often extending well above and below the 500-point mark depending on the age and cognitive ability of the individual.

    Time frame: 8 weeks

  18. Phase 3: The PK parameters of codabakalner concentrations in plasma-Cmax

    Maximum concentration of drug in plasma following dose

    Time frame: 12 weeks

  19. Phase 3: Change in from baseline to Week 4, Week 8, and Week 12, in ABC total score and subscale scores (FXS scoring)

    The Aberrant Behavior Checklist-Community edition (ABC-C) is a 58-item, caregiver-rated symptom checklist for assessing problem behaviors of children and adults with mental retardation at home, in residential facilities, and work training centers. The assessment was done by attributing to each item a score from 0 ("not at all a problem") to 3 ("problem is severe in degree") The ABC will be scored using the FXS-specific factoring system (ABC-FX) for which the total score ranks from 0 to 165.

    Time frame: 12 weeks

  20. Phase 3: Change from baseline to Week 4, Week 8, and Week 12 in behaviors and other symptoms on NRS by caregiver

    Numerical rating scale (NRS) scores based on patient-specific behaviors within the domains of Daily Function, Language, and Academic Skill. Caregiver will rate individual from 0 to 10, where 0 indicates 'worst problem' and 10 indicates' no problem at all.'

    Time frame: 12 weeks

  21. Phase 3: Change from baseline to Week 12 in Vineland Adaptive Behavior Scale 3rd Edition

    Vineland-3 Adaptive Behavior Scale (Vineland-3), using the composite score and domain scores from communication, daily living skills, and socialization. The adaptive behavior composite standard score is computed from the sum of standard scores from the domains and converted into the adaptive behavior composite standard score. Higher scores indicate a higher adaptive level of functioning.

    Time frame: 12 weeks

  22. Phase 3: Change from baseline in CGI-S as assessed by investigator

    This is a 7-point clinician-rated tool used to measure how ill a patient is at the time of assessment

    Time frame: 12 weeks

  23. Phase 3: Change from baseline in CGI-I as assessed by investigator

    The Clinical Global Impression-Improvement (CGI-I) scale is a clinician rated scale used to assess treatment response. The score ranges from 1 to 7 (with 1 being "very much improved", 4 being "no change" to 7 being "very much worse")

    Time frame: 12 weeks

  24. Phase 3: Change from baseline in Caregiver Global Impression of Improvement (CGI-C) assessments

    The Caregiver Global Impression of Improvement (CGI-C) is a global measure to provide a caregiver's perspective of a subject's overall condition. The caregiver will use a 7-point scale to assess how the condition has changed from baseline. A higher number indicates worsening condition.

    Time frame: 12 weeks

  25. Phase 3: Change from baseline in the Numerical Rating Scale at Week 4, Week 8, and Week 12 as completed by the caregiver

    Numerical rating scale (NRS) scores based on patient-specific behaviors within the domains of Daily Function, Language, and Academic Skill. Caregiver will rate individual from 0 to 10, where 0 indicates 'worst problem' and 10 indicates' no problem at all.'

    Time frame: 12 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for Feb 2030, 38 months later.

Start moved once since we started tracking on Sep 25, 2026: Mar 2026 → Dec 2026, on Oct 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2026
First posted
Feb 27, 2026
StartEst.
Dec 1, 2026was Mar 2026
Primary completionEst.
Feb 1, 2030
CompletionEst.
Jun 30, 2030
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Mar 1, 2026→Dec 1, 2026
Oct 9, 2026
Enrollment
248→120
Oct 9, 2026
Eligibility
2 inclusion criteria edited, 1 added; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedPhase 2b: Adult males aged 18 to 45 years, inclusive Phase 3: Males aged 13-45 years, inclusive Mental age >/= 36mon
  • EditedDiagnosis of Fragile X as confirmed with genetic testing and Stanford Binet testing or
  • AddedConfirmed diagnosis ASD per DSM5-TR and EEG criteria
Exclusion criteria
  • EditedHistory of suicidal behaviorbehaviour or suicidal ideation
  • EditedECG that are abnormal and clinically significant abnormal
Oct 9, 2026
Interventions
Changed SPG601→Codabakalner. Arm changed Phase 2b: Active comparator→Phase 2b: Active; Phase 3: Active comparator→Phase 3: Active
Oct 9, 2026
Primary outcomes
3 edited
What changed in the outcomes
  • EditedPhase 2b: FXS- Change from baseline in Total Cognition Composite Change Sensitive Score from the NIH-TCBTime frame: 8 weeks → 28 days
  • EditedPhase 3: FXS - Change from baseline in Total Cognition Composite score from the NIH-TCBTime frame: 12 weeks
  • ChangedBefore Phase 2b: Change from baseline in EEG resting state relative power bands during restNow Phase 2b: ASD - Change from Baseline at Day 28 on the Vineland Adaptive Behavior Scales in ASD(Vineland-III) Adaptive Behavior Composite ScoreTime frame: 8 weeks → 28 days
Oct 9, 2026
Secondary outcomes
12 edited, 2 time frame changed, 8 added, 4 removed
What changed in the outcomes
  • EditedPhase 2b: FXS- Change from baseline in Fluid Reasoning Composite Change Sensitive Scores from the NIH-TCBTime frame: 8 weeks → 28 days
  • EditedPhase 2b: FXS- Change from baseline in Flanker Scores from the NIH-TCBTime frame: 8 weeks → 28 days
  • EditedPhase 2b: FXS and ASD - Incidence, nature, and severity of adverse events (AEs) and serious adverse events (SAEs)Time frame: 8 weeks → 28 days
  • EditedPhase 2b: FXS and ASD - Change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) throughout the studyTime frame: 8 weeks → 28 days
  • EditedPhase 2b: FXS and ASD - The PK parameters of SPG601codabakalner concentrations in plasma-CmaxTime frame: 4 weeks → 28 days
  • EditedPhase 2b3: The PK parameters of SPG601codabakalner concentrations in plasma-T 1/2CmaxTime frame: 4 weeks → 12 weeks
  • EditedPhase 3: Change from baseline to week 12 in Flanker ScoresTotal Cognition Composite score from the NIH-TCBTime frame: 12 weeks
  • EditedPhase 3: Change from baseline to Week 4, Week 8, and Week 12 in Fluid Reasoning Composite Change Sensitive ScoresFlanker from the NIH-TCBTime frame: 12 weeks
  • EditedPhase 3: Change from baseline to Week 4, Week 8, and Week 12 in behaviors and other symptoms on Numerical Rating System (NRS) by caregiverTime frame: 12 weeks
  • EditedPhase 32b: FXS and ASD: Change from baseline at Day 28 in Caregiver Global ImpressionClinical global impression of Improvementseverity (CaGICGI-IS) assessmentsas assessed by the investigatorTime frame: 12 weeks → 28 days
  • EditedPhase 3 substudy2b: FXS and ASD: Change from baseline to Day 28 in EEG resting state relative power in the alpha, theta, and gamma bands during restTime frame: 12 weeks → 28 days
  • ChangedBefore Phase 3: Change From Baseline in Behavioral Symptoms of Fragile X Syndrome Using the Aberrant Behavior Checklist (ABC) Total Score in StratumNow Phase 3: Change in from baseline to Week 4, Week 8, and Week 12, in ABC total score and subscale scores (FXS scoring)Time frame: 12 weeks
  • AddedPhase 2b- FXS Change from Baseline at Day 28 on the Vineland Adaptive Behavior Scales (Vineland-III) Adaptive Behavior Composite ScoreTime frame: 28 days
  • AddedPhase 2b: FXS and ASD: Change from baseline at Day 28 in Clinical global impression of improvement as assessed by the investigatorTime frame: 28 days
  • AddedPhase 2b: FXS and ASD: Change from baseline at Day 28 in Caregiver global impression of change (CGI-C) as assessed by the caregiverTime frame: 28 days
  • AddedPhase 2b: FXS and ASD: Change from baseline at Day 28 in the Numerical Rating Scale as completed by the caregiverTime frame: 28 days
  • AddedPhase 3: Change from baseline to Week 4, Week 8, and Week 12 in Fluid Reasoning Composite Change Sensitive Scores from the NIH-TCBTime frame: 12 weeks
  • AddedPhase 3: Change from baseline in CGI-S as assessed by investigatorTime frame: 12 weeks
  • AddedPhase 3: Change from baseline in Caregiver Global Impression of Improvement (CGI-C) assessmentsTime frame: 12 weeks
  • AddedPhase 3: Change from baseline in the Numerical Rating Scale at Week 4, Week 8, and Week 12 as completed by the caregiverTime frame: 12 weeks
  • RemovedPhase 3: Change from baseline in the Anxiety, Depression and Mood Scale (ADAMS)Time frame: 12 weeks
  • RemovedPhase 3: The PK parameters of SPG601 concentrations in plasma-CmaxTime frame: 12 weeks
  • RemovedPhase 3: The PK parameters of SPG601 concentrations in plasma-T 1/2Time frame: 12 weeks
  • RemovedPhase 3 substudy: Change from baseline in the gamma range in response to the chirp stimulus and to the steady state stimuliTime frame: 12 weeks
  • Time framePhase 3: Incidence, nature, and severity of adverse events (AEs) and serious adverse events (SAEs)16 weeks → 12 weeks
  • Time framePhase 3: Change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) throughout the study8 weeks → 12 weeks
Oct 9, 2026
Contact
Study contact changed: •••3842→•••5695; added c•••@spinogenix.com · •••3842. See the current contact
Oct 9, 2026
Title
A Study to Investigate the Effects and Safety of SPG601Codabakalner for the Treatment of Fragile X SyndromeFXS in Male Participants and Adult Participants With ADS
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Start date Mar 1, 2026→Dec 1, 2026
    Enrollment 248→120
    Eligibility 2 inclusion criteria edited, 1 added; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedPhase 2b: Adult males aged 18 to 45 years, inclusive Phase 3: Males aged 13-45 years, inclusive Mental age >/= 36mon
    • EditedDiagnosis of Fragile X as confirmed with genetic testing and Stanford Binet testing or
    • AddedConfirmed diagnosis ASD per DSM5-TR and EEG criteria
    Exclusion criteria
    • EditedHistory of suicidal behaviorbehaviour or suicidal ideation
    • EditedECG that are abnormal and clinically significant abnormal
    Primary outcomes 3 edited
    What changed in the outcomes
    • EditedPhase 2b: FXS- Change from baseline in Total Cognition Composite Change Sensitive Score from the NIH-TCBTime frame: 8 weeks → 28 days
    • EditedPhase 3: FXS - Change from baseline in Total Cognition Composite score from the NIH-TCBTime frame: 12 weeks
    • ChangedBefore Phase 2b: Change from baseline in EEG resting state relative power bands during restNow Phase 2b: ASD - Change from Baseline at Day 28 on the Vineland Adaptive Behavior Scales in ASD(Vineland-III) Adaptive Behavior Composite ScoreTime frame: 8 weeks → 28 days
    Secondary outcomes 12 edited, 2 time frame changed, 8 added, 4 removed
    What changed in the outcomes
    • EditedPhase 2b: FXS- Change from baseline in Fluid Reasoning Composite Change Sensitive Scores from the NIH-TCBTime frame: 8 weeks → 28 days
    • EditedPhase 2b: FXS- Change from baseline in Flanker Scores from the NIH-TCBTime frame: 8 weeks → 28 days
    • EditedPhase 2b: FXS and ASD - Incidence, nature, and severity of adverse events (AEs) and serious adverse events (SAEs)Time frame: 8 weeks → 28 days
    • EditedPhase 2b: FXS and ASD - Change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) throughout the studyTime frame: 8 weeks → 28 days
    • EditedPhase 2b: FXS and ASD - The PK parameters of SPG601codabakalner concentrations in plasma-CmaxTime frame: 4 weeks → 28 days
    • EditedPhase 2b3: The PK parameters of SPG601codabakalner concentrations in plasma-T 1/2CmaxTime frame: 4 weeks → 12 weeks
    • EditedPhase 3: Change from baseline to week 12 in Flanker ScoresTotal Cognition Composite score from the NIH-TCBTime frame: 12 weeks
    • EditedPhase 3: Change from baseline to Week 4, Week 8, and Week 12 in Fluid Reasoning Composite Change Sensitive ScoresFlanker from the NIH-TCBTime frame: 12 weeks
    • EditedPhase 3: Change from baseline to Week 4, Week 8, and Week 12 in behaviors and other symptoms on Numerical Rating System (NRS) by caregiverTime frame: 12 weeks
    • EditedPhase 32b: FXS and ASD: Change from baseline at Day 28 in Caregiver Global ImpressionClinical global impression of Improvementseverity (CaGICGI-IS) assessmentsas assessed by the investigatorTime frame: 12 weeks → 28 days
    • EditedPhase 3 substudy2b: FXS and ASD: Change from baseline to Day 28 in EEG resting state relative power in the alpha, theta, and gamma bands during restTime frame: 12 weeks → 28 days
    • ChangedBefore Phase 3: Change From Baseline in Behavioral Symptoms of Fragile X Syndrome Using the Aberrant Behavior Checklist (ABC) Total Score in StratumNow Phase 3: Change in from baseline to Week 4, Week 8, and Week 12, in ABC total score and subscale scores (FXS scoring)Time frame: 12 weeks
    • AddedPhase 2b- FXS Change from Baseline at Day 28 on the Vineland Adaptive Behavior Scales (Vineland-III) Adaptive Behavior Composite ScoreTime frame: 28 days
    • AddedPhase 2b: FXS and ASD: Change from baseline at Day 28 in Clinical global impression of improvement as assessed by the investigatorTime frame: 28 days
    • AddedPhase 2b: FXS and ASD: Change from baseline at Day 28 in Caregiver global impression of change (CGI-C) as assessed by the caregiverTime frame: 28 days
    • AddedPhase 2b: FXS and ASD: Change from baseline at Day 28 in the Numerical Rating Scale as completed by the caregiverTime frame: 28 days
    • AddedPhase 3: Change from baseline to Week 4, Week 8, and Week 12 in Fluid Reasoning Composite Change Sensitive Scores from the NIH-TCBTime frame: 12 weeks
    • AddedPhase 3: Change from baseline in CGI-S as assessed by investigatorTime frame: 12 weeks
    • AddedPhase 3: Change from baseline in Caregiver Global Impression of Improvement (CGI-C) assessmentsTime frame: 12 weeks
    • AddedPhase 3: Change from baseline in the Numerical Rating Scale at Week 4, Week 8, and Week 12 as completed by the caregiverTime frame: 12 weeks
    • RemovedPhase 3: Change from baseline in the Anxiety, Depression and Mood Scale (ADAMS)Time frame: 12 weeks
    • RemovedPhase 3: The PK parameters of SPG601 concentrations in plasma-CmaxTime frame: 12 weeks
    • RemovedPhase 3: The PK parameters of SPG601 concentrations in plasma-T 1/2Time frame: 12 weeks
    • RemovedPhase 3 substudy: Change from baseline in the gamma range in response to the chirp stimulus and to the steady state stimuliTime frame: 12 weeks
    • Time framePhase 3: Incidence, nature, and severity of adverse events (AEs) and serious adverse events (SAEs)16 weeks → 12 weeks
    • Time framePhase 3: Change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) throughout the study8 weeks → 12 weeks
    Interventions Changed SPG601→Codabakalner. Arm changed Phase 2b: Active comparator→Phase 2b: Active; Phase 3: Active comparator→Phase 3: Active
    Contact Study contact changed: •••3842→•••5695; added c•••@spinogenix.com · •••3842. See the current contact
    Title A Study to Investigate the Effects and Safety of SPG601Codabakalner for the Treatment of Fragile X SyndromeFXS in Male Participants and Adult Participants With ADS
    + 4 other changes: index terms, verification date, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07439510
Lead sponsor
Spinogenix
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Feb 1, 2030 (estimated)
Completion
Jun 30, 2030 (estimated)
Last update
Oct 9, 2026

Study contacts

Contact
Contact
contact@spinogenix.com
(310) 853-5695
COntacvt Back up
Contact
contact@spinogenix.com
‪(503) 673-3842‬

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion